Harpoon Therapeutics Trispecific Protein BCMA Patent Application
Summary
Harpoon Therapeutics, Inc. filed patent application US20260109773A1 covering B cell maturation agent (BCMA) targeting trispecific proteins. The disclosed proteins comprise a CD3 binding domain, a half-life extension domain, and a BCMA binding domain, along with pharmaceutical compositions, nucleic acids, and methods of use for treating diseases and disorders. Application No. 19249844 was filed June 25, 2025, with inventors Holger Wesche, Bryan D. Lemon, and Richard J. Austin listed.
“Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Harpoon Therapeutics, Inc. published patent application US20260109773A1 for trispecific proteins targeting BCMA (B cell maturation agent) for therapeutic applications. The disclosed BCMA targeting proteins include a CD3 binding domain, a half-life extension domain, and a BCMA binding domain, with pharmaceutical composition and nucleic acid embodiments also covered.
For entities in the pharmaceutical and biotechnology sectors, this publication establishes prior art in the trispecific antibody/protein space. Companies developing similar multi-domain therapeutic proteins targeting BCMA or related antigens should evaluate potential freedom-to-operate implications and monitor the prosecution of this application.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRISPECIFIC PROTEINS AND METHODS OF USE
Application US20260109773A1 Kind: A1 Apr 23, 2026
Assignee
Harpoon Therapeutics, Inc.
Inventors
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
Abstract
Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
CPC Classifications
C07K 16/2878 A61K 39/395 A61P 35/00 C07K 16/18 C07K 16/2809 C07K 2317/21 C07K 2317/24 C07K 2317/31 C07K 2317/56 C07K 2317/565 C07K 2317/569 C07K 2317/622 C07K 2317/732 C07K 2317/76 C07K 2317/92 C07K 2319/30 C07K 2319/31
Filing Date
2025-06-25
Application No.
19249844
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.